Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Treating Narcolepsy with Once Nightly Controlled-Release Sodium Oxybate with Dr. Jennifer Gudeman Avadel Pharmaceuticals TRANSCRIPT
Download PDFJun 29, 2021
Dr. Jennifer Gudeman was hired for the newly formed role of Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals. We talk about the clinical development of their lead investigational product FT218 to treat the rare disease narcolepsy. Optimized the drug delivery release of sodium oxybate with their proprietary controlled-release technology allows for a single bedtime dose.
While the FDA nearly 20 years ago approved sodium oxybate to treat cataplexy and excessive daytime sleepiness, the drug was an immediate-release medication requiring a middle-of-the-night dose. After a successful Phase 3 clinical trial, Avadel's ongoing open-label study, RESTORE, is providing evidence that points to more restorative sleep across a broad audience.
@AvadelPharma $AVDL #narcolepsy #rarediseases #cataplexy #sleepdisorders #sleep #EDS #neurotwitter
